MA28335A1 - Agonistes du recepteur (vpac2) du type peptides activant l'adenylate cyclase hypophysaire (pacap) et procedes pharmacologiques d'utilisation de ces agonistes - Google Patents
Agonistes du recepteur (vpac2) du type peptides activant l'adenylate cyclase hypophysaire (pacap) et procedes pharmacologiques d'utilisation de ces agonistesInfo
- Publication number
- MA28335A1 MA28335A1 MA29206A MA29206A MA28335A1 MA 28335 A1 MA28335 A1 MA 28335A1 MA 29206 A MA29206 A MA 29206A MA 29206 A MA29206 A MA 29206A MA 28335 A1 MA28335 A1 MA 28335A1
- Authority
- MA
- Morocco
- Prior art keywords
- agonists
- vpac2
- receptor
- hypophysic
- pacap
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 3
- 102100038286 Vasoactive intestinal polypeptide receptor 2 Human genes 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 101000666868 Homo sapiens Vasoactive intestinal polypeptide receptor 2 Proteins 0.000 title 1
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 title 1
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 title 1
- 102000030621 adenylate cyclase Human genes 0.000 title 1
- 108060000200 adenylate cyclase Proteins 0.000 title 1
- 102000014187 peptide receptors Human genes 0.000 title 1
- 108010011903 peptide receptors Proteins 0.000 title 1
- 230000000144 pharmacologic effect Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 239000008103 glucose Substances 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 229940122199 Insulin secretagogue Drugs 0.000 abstract 1
- 101710137651 Vasoactive intestinal polypeptide receptor 2 Proteins 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 208000016097 disease of metabolism Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000003914 insulin secretion Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53955004P | 2004-01-27 | 2004-01-27 | |
| US56649904P | 2004-04-29 | 2004-04-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA28335A1 true MA28335A1 (fr) | 2006-12-01 |
Family
ID=34830483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA29206A MA28335A1 (fr) | 2004-01-27 | 2006-07-24 | Agonistes du recepteur (vpac2) du type peptides activant l'adenylate cyclase hypophysaire (pacap) et procedes pharmacologiques d'utilisation de ces agonistes |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090143283A1 (OSRAM) |
| EP (1) | EP1713493A4 (OSRAM) |
| JP (1) | JP2007519739A (OSRAM) |
| KR (1) | KR20070009554A (OSRAM) |
| AU (1) | AU2005208911A1 (OSRAM) |
| BR (1) | BRPI0507177A (OSRAM) |
| CA (1) | CA2554475A1 (OSRAM) |
| EC (1) | ECSP066793A (OSRAM) |
| IL (1) | IL176705A0 (OSRAM) |
| MA (1) | MA28335A1 (OSRAM) |
| NO (1) | NO20063801L (OSRAM) |
| RU (1) | RU2006130691A (OSRAM) |
| WO (1) | WO2005072385A2 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1768686A4 (en) * | 2004-06-12 | 2007-11-14 | Bayer Pharmaceuticals Corp | PEGYLATION OF VASOACTIVE INTESTINAL PEPTIDE (VIP) / HYPOPHYDE-ADENYLATE CYCLASE-ACTIVATING PEPTIDE (PACAP) RECEPTOR 2 (VPAC2) AGONISTS AND METHOD OF USE |
| EP1896048A4 (en) * | 2005-05-06 | 2010-11-03 | Bayer Pharmaceuticals Corp | PEPTIDE RECEPTOR (VPAC2) AGONISTS THAT ACTIVATE HYPOPHYSIC ADENYLATE CYCLASE (PACAP) AND THEIR PHARMACOLOGICAL METHODS OF USE |
| BRPI0617740A2 (pt) * | 2005-10-26 | 2011-08-02 | Lilly Co Eli | agonistas seletivos peptìdicos do receptor vpac2, composição farmacêutica e uso dos referidos agonistas |
| CA2797033C (en) | 2010-04-22 | 2021-10-19 | Longevity Biotech, Inc. | Highly active polypeptides and methods of making and using the same |
| WO2014145718A2 (en) | 2013-03-15 | 2014-09-18 | Longevity Biotech, Inc. | Peptides comprising non-natural amino acids and methods of making and using the same |
| KR20180002685A (ko) | 2015-04-16 | 2018-01-08 | 앨더 바이오파마슈티컬즈, 인코포레이티드 | 항-pacap 항체 및 그의 용도 |
| SG10202109691UA (en) | 2016-04-15 | 2021-10-28 | Alder Biopharmaceuticals Inc | Anti-pacap antibodies and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU656230B2 (en) * | 1991-10-11 | 1995-01-27 | F. Hoffmann-La Roche Ag | Cyclic vasoactive peptides |
| ATE397625T1 (de) * | 1999-09-28 | 2008-06-15 | Bayer Corp | Agonisten des rezeptors 3 (r3) von pituitary adenylate cyclase aktivierendem peptid (pacap) und ihre pharmakologische verwendung |
| CA2472956A1 (en) * | 2002-02-14 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Formulation strategies in stabilizing peptides in organic solvents and in dried states |
| WO2004006839A2 (en) * | 2002-07-12 | 2004-01-22 | Bayer Pharmaceuticals Corporation | Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use |
-
2005
- 2005-01-27 AU AU2005208911A patent/AU2005208911A1/en not_active Abandoned
- 2005-01-27 CA CA002554475A patent/CA2554475A1/en not_active Abandoned
- 2005-01-27 KR KR1020067015124A patent/KR20070009554A/ko not_active Withdrawn
- 2005-01-27 BR BRPI0507177-1A patent/BRPI0507177A/pt not_active IP Right Cessation
- 2005-01-27 EP EP05712166A patent/EP1713493A4/en not_active Withdrawn
- 2005-01-27 US US10/586,124 patent/US20090143283A1/en not_active Abandoned
- 2005-01-27 JP JP2006551478A patent/JP2007519739A/ja active Pending
- 2005-01-27 WO PCT/US2005/002609 patent/WO2005072385A2/en not_active Ceased
- 2005-01-27 RU RU2006130691/15A patent/RU2006130691A/ru not_active Application Discontinuation
-
2006
- 2006-07-04 IL IL176705A patent/IL176705A0/en unknown
- 2006-07-24 MA MA29206A patent/MA28335A1/fr unknown
- 2006-08-25 NO NO20063801A patent/NO20063801L/no not_active Application Discontinuation
- 2006-08-25 EC EC2006006793A patent/ECSP066793A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005072385A3 (en) | 2006-06-08 |
| NO20063801L (no) | 2006-10-26 |
| CA2554475A1 (en) | 2005-08-11 |
| WO2005072385A2 (en) | 2005-08-11 |
| ECSP066793A (OSRAM) | 2006-11-16 |
| EP1713493A2 (en) | 2006-10-25 |
| EP1713493A4 (en) | 2009-06-24 |
| IL176705A0 (en) | 2006-10-31 |
| RU2006130691A (ru) | 2008-03-10 |
| KR20070009554A (ko) | 2007-01-18 |
| JP2007519739A (ja) | 2007-07-19 |
| AU2005208911A1 (en) | 2005-08-11 |
| US20090143283A1 (en) | 2009-06-04 |
| BRPI0507177A (pt) | 2007-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Henning et al. | Vasoactive intestinal peptide: cardiovascular effects | |
| Larsen et al. | Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats | |
| Deacon et al. | Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs | |
| Brown et al. | Brain peptide regulation of adrenal epinephrine secretion | |
| Egan et al. | Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes | |
| Dogrukol-Ak et al. | Passage of VIP/PACAP/secretin family across the blood-brain barrier: therapeutic effects | |
| Cabou et al. | Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity | |
| Bratusch-Marrain et al. | Efficacy of pulsatile versus continuous insulin administration on hepatic glucose production and glucose utilization in type I diabetic humans | |
| Ludvik et al. | Amylin: history and overview | |
| DE60016393T2 (de) | Metabolische intervention mit glp-1 zur verbesserung der funktion von ischämischem und wiederdurchblutetem gewebe | |
| Jensen et al. | C-peptide induces a concentration-dependent dilation of skeletal muscle arterioles only in presence of insulin | |
| BR0312621A (pt) | Agonistas de receptor (vpac2) de peptìdeo de ativação de pituitária adenilato ciclase (pacap) | |
| Ahlborg et al. | Metabolic and vascular effects of circulating endothelin-1 during moderately heavy prolonged exercise | |
| MA28335A1 (fr) | Agonistes du recepteur (vpac2) du type peptides activant l'adenylate cyclase hypophysaire (pacap) et procedes pharmacologiques d'utilisation de ces agonistes | |
| Bray | Food intake, sympathetic activity, and adrenal steroids | |
| Yokota et al. | PACAP stimulates glucose output from the perfused rat liver | |
| EP1976548A1 (en) | Vip fragments and methods of use | |
| Sanfield et al. | Epinephrine increases plasma immunoreactive atrial natriuretic hormone levels in humans | |
| Antoniou et al. | Differential effects of the neuropeptide galanin on striatal acetylcholine release in anaesthetized and awake rats | |
| Wang et al. | Cardiovascular actions of python bradykinin and substance P in the anesthetized python, Python regius | |
| Malendowicz et al. | Effects of prolonged exendin-4 administration on entero-insular axis of normal and streptozotocin-induced diabetic rats | |
| Mohan | Which insulin to use? Human or animal? | |
| Ahrén et al. | Interaction of vasoactive intestinal peptide (VIP) with cholinergic stimulation of glucagon secretion | |
| Patil et al. | Role of insulin in management of type 2 diabetes mellitus | |
| Gürün et al. | Intracerebroventricular choline reverses hypotension induced by acute chemical sympathectomy |